Axsome Third Quarter 2026 Financial Results - AXSOME THERAPEUTICS INC

Financial Performance:

• Total revenue reached $259.7 million in Q3 2026, representing a 52% year-over-year (YoY) increase and 19% sequential growth.
• Avelity net product sales were $207.6 million (53% YoY growth, >15% sequential increase), exceeding $1 billion annual run rate.
• NOSI segment generated $48.2 million ($38.5M sales + $1.2B royalties + $8.5B milestone revenue); Sembravo net sales were $3.9 million (88% YoY growth).
• Gross margin remained robust in the low-to-mid 90% range; gross net discounts for Avelity and Synosy improved to the mid-to-high 40s range.
• Operating expenses: Cost of revenue $17.8M; R&D $50.6M (up from $40.2M YoY due to late-stage clinical costs); SG&A $203.1M (driven by commercialization, flat sequentially).
• Net loss narrowed significantly to $12.9 million ($0.25/share) from $47.2 million ($0.94/share) YoY; loss included $26.4M in stock-based compensation.
• Cash and cash equivalents ended the quarter at approximately $314 million; management expects this balance to fund operations through cash flow positivity.

Guidance and Future Outlook:

• Management expects sustained momentum in demand for MDD and acceleration in new patient initiations for Alzheimer's disease agitation (ADA).
• Avelity is projected to generate at least $8 billion in peak annual revenue.
• Q4 gross net discounts for Avelity and Sembravo are anticipated to tick up slightly due to seasonality and accruals for Q1 adjudications.
• Long-term goals include delivering multiple new products across the 10-program neuroscience pipeline and expanding label opportunities for existing assets.
• No specific Q4 or 2027 financial guidance was provided, but the company anticipates continued revenue growth and operating leverage.

Business Segments and Product Lines:

• Avelity (NOSI): Prescriptions reached 302,000 (40% YoY, 14% sequential); new-to-brand prescriptions grew 211% YoY in the 65+ demographic (ADA indication). Expanded prescriber base to ~77,000 unique providers, with primary care now representing nearly 40% of prescribers.
• Sembravo: Achieved 25,000+ total prescriptions (382% YoY growth); outperforming the broader migraine market. Payer coverage stands at ~57% of lives.
• Synosy: Recorded 64,400+ prescriptions (15% YoY growth); coverage at ~82% of lives.
• Pipeline Progress:
  • AXS-05 (NOSI): Phase 3 smoking cessation trial initiated; top-line data expected H2 2027.
  • Solriamfetol (AXS-12): Label expansion trials for ADHD (Focus 2/3, results H2 2027), Binge Eating Disorder (ENGAGE, results H1 2027), and shift work disorder (results H2 2027).
  • AXS-20 (PDE10A inhibitor): Pivotal Phase 3 schizophrenia trial planned for H1 2027; Tourette's remains a secondary indication.
  • AXS-12 (Orexin-2 agonist): NDA for narcolepsy/cataplexy under review; PDUFA date May 1, 2027.
  • AXS-14 (Fibromyalgia): Phase 3 enrollment completion expected Q3 2027; NDA filing anticipated shortly after if positive.
  • AXS-17 (Epilepsy): Clinical trials planned for H1 2027.

Market and Competitive Landscape:

• Avelity is outpacing the antidepressant market (growing 40% vs 3% YoY) and showing significant share gains in the nascent ADA agitation market, which lacks precedent.
• Primary care is identified as the fastest-growing segment for Avelity adoption across both MDD and ADA indications.
• Sembravo addresses a gap in patients with inadequate response to prior acute migraine treatments, showing rapid symptom relief.
• Synosy maintains durable growth in the weight-promoting agent market, which saw flat YoY growth in competitors.
• The narcolepsy market is characterized by heterogeneous responses to existing therapies, positioning AXS-12 as a differentiated option.

Risks and Challenges:

• Payer Dynamics: Patient affordability and conversion from samples to paid prescriptions remain key monitoring areas, particularly for Medicare patients.
• Market Education: Significant ongoing education is required for the ADA agitation market regarding symptom identification and diagnosis.
• Clinical Trial Risks: Potential for rising placebo rates in schizophrenia trials; management is utilizing proprietary protocol designs to mitigate this.
• Regulatory/Operational: No major bottlenecks identified for ADA launch, though EMR updates are necessary; third-party data capture rates (IQVIA/Symphony) experienced temporary fluctuation.

Management Commentary and Tone:

• Tone was confident and robust, emphasizing "continued commercial progress," "sustained momentum," and "improving fundamentals."
• Management highlighted operating leverage, noting the reduction in net loss despite significant commercial expansion.
• Executive team expressed strong conviction in the commercial potential of Avelity and the pipeline's ability to deliver innovation.
• Leadership emphasized that Q3 results met internal expectations and that stock price performance does not reflect underlying business execution.

Analyst Questions and Answers:

• Sample Conversion: Confirmed sampling rates match MDD launch; positive new-to-brand growth observed among sampled HCPs.
• Rexulti Comparison: Avoided direct comparison but noted Avelity operates in a new, developing market requiring education on agitation symptoms.
• Sales Force Productivity: Confirmed the sales expansion is driving growth, with under-65 TRX growing 32% post-expansion.
• LTC Opportunity: Long-term care channel performing well with growth rates similar to the 65+ population; distinct sales cycle but positive value proposition.
• Pricing/Access: Payer dialogue for AXS-12 is positive; no specific pricing comments prior to launch.
• Data Sources: Acknowledged temporary fluctuations in data capture rates due to new pharmacy reporting behaviors.

Other Key Points:

• Avelity has achieved ~89% coverage of total lives (100% of government channel).
• The company executed two BD transactions recently (schizophrenia and epilepsy assets) which are now integrated into the pipeline without impacting Avelity's growth strategy.
• No formal decision was made to remove Tourette's from the AXS-20 pipeline; it is simply deprioritized relative to schizophrenia for current public disclosure.
• The company plans to utilize proprietary "bells and whistles" in clinical trial designs to manage high placebo response rates.